Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Contineum Therapeutics, Inc. - Common stock (CTNM)
Company Research
Source: Business Wire
- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl -- Strong cash position of $219 million at the end of Q2 will support multiple clinical readouts - SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress.“Our team has made great progress in the last several months with a continued focus on achieving our corporate milestones. We accelerated enrollment in our ongoing Phase 2 clinical trial of PIPE-307 for relapsed-remitting multiple sclerosis (RRMS), added top-level talent to our leade
Show less
Read more
Impact Snapshot
Event Time:
CTNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTNM alerts
High impacting Contineum Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CTNM
News
- Contineum Therapeutics to Present at Multiple Upcoming Investor ConferencesBusiness Wire
- Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its price target raised by analysts at Royal Bank of Canada from $30.00 to $32.00. They now have an "outperform" rating on the stock.MarketBeat
- Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple SclerosisBusiness Wire
CTNM
Earnings
- 8/13/24 - Miss
CTNM
Sec Filings
- 8/14/24 - Form 4
- 8/14/24 - Form 10-Q
- 8/14/24 - Form 8-K/A
- CTNM's page on the SEC website